UCLA study: A metabolic process in cancer cells points to novel treatment for glioblastoma

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.

June 28, 2024

Vol.50 No.26

Clinical Roundup

AI improves physicians’ ability to identify prostate cancer extent

Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.

June 14, 2024

Vol.50 No.24

Clinical Roundup

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

In Brief

Dennis Slamon receives Szent-Györgyi Prize from National Foundation for Cancer Research

Dennis Slamon, an oncologist and scientist whose research has transformed the treatment of breast cancer, was awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting.

May 31, 2024

Vol.50 No.22

Clinical Roundup

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

Women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline in physical function, a UCLA-led study suggests.

May 17, 2024

Vol.50 No.20

UCLA study: A metabolic process in cancer cells points to novel treatment for glioblastoma

YOU MAY BE INTERESTED IN

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

AI improves physicians’ ability to identify prostate cancer extent

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Dennis Slamon receives Szent-Györgyi Prize from National Foundation for Cancer Research

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

Renew today!

Subscriber content

Login